{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:12:42Z","timestamp":1791378762742,"version":"4.3.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n              <jats:title>Background<\/jats:title>\n              <jats:p>Randomized sham-controlled trials have confirmed the efficacy and safety of catheter-based renal denervation in hypertension. Data on the very long-term effects of renal denervation are scarce.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Aims<\/jats:title>\n              <jats:p>This study evaluates the 10-year safety and efficacy of renal denervation in resistant hypertension.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Methods<\/jats:title>\n              <jats:p>This prospective single-center study included patients with resistant hypertension undergoing radio-frequency renal denervation between 2010 and 2012. Office blood pressure, 24-h ambulatory blood pressure, antihypertensive medication, color duplex sonography, and renal function were assessed after 1-, 2- and 10-years.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Results<\/jats:title>\n              <jats:p>Thirty-nine patients completed the 10-year follow-up (mean follow-up duration 9.4\u2009\u00b1\u20090.7\u00a0years). Baseline office and 24-h ambulatory systolic blood pressure were 164\u2009\u00b1\u200923\u00a0mmHg and 153\u2009\u00b1\u200916\u00a0mmHg, respectively. After 10\u00a0years, 24-h ambulatory and office systolic blood pressure were reduced by 16\u2009\u00b1\u200917\u00a0mmHg (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and 14\u2009\u00b1\u200923\u00a0mmHg (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), respectively. The number of antihypertensive drugs remained unchanged from 4.9\u2009\u00b1\u20091.4 to 4.5\u2009\u00b1\u20091.2 drugs (<jats:italic>P<\/jats:italic>\u2009=\u20090.087). The estimated glomerular filtration rate declined within the expected range from 69 (95% CI 63 to 74) to 60\u00a0mL\/min\/1.73m<jats:sup>2<\/jats:sup> (95% CI 53 to 68; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) through 10-year follow-up. Three renal artery interventions were documented for progression of pre-existing renal artery stenosis in two patients and one patient with new-onset renal artery stenosis. No other adverse events were observed during the follow-up.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Conclusion<\/jats:title>\n              <jats:p>Renal denervation was safe and sustainedly reduced ambulatory and office blood pressure out to 10\u00a0years in patients with resistant hypertension.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Graphical abstract<\/jats:title>\n              <jats:p>Left panel, Change in 24-h and office SBP. Right panel, eGFR over time. SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate.<\/jats:p>\n              \n            <\/jats:sec>","DOI":"10.1007\/s00392-024-02417-2","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:02:35Z","timestamp":1709798555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0142-4908","authenticated-orcid":false,"given":"Hussam","family":"Al Ghorani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saarraaken","family":"Kulenthiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-9556","authenticated-orcid":false,"given":"Lucas","family":"Lauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Johannes Maria","family":"Recktenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Dederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"G\u00f6tzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ukena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2417_CR1","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1161\/CIR.0000000000000596","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ 138:e484\u2013e594. https:\/\/doi.org\/10.1161\/CIR.0000000000000596","journal-title":"Circ"},{"key":"2417_CR2","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 39:3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"2417_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/HYPERTENSIONAHA.120.16418","volume":"78","author":"BM Egan","year":"2021","unstructured":"Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD (2021) Hypertension control in the United States 2009 to 2018: factors underlying falling control rates during 2015 to 2018 across age- and race-ethnicity groups. Hypertension 78:578\u2013587. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16418","journal-title":"Hypertension"},{"key":"2417_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/cphy.c100043","volume":"1","author":"EJ Johns","year":"2011","unstructured":"Johns EJ, Kopp UC, Dibona GF (2011) Neural control of renal function. Compr Physiol 1:731\u2013767. https:\/\/doi.org\/10.1002\/cphy.c100043","journal-title":"Compr Physiol"},{"key":"2417_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41569-020-0364-1","volume":"17","author":"L Lauder","year":"2020","unstructured":"Lauder L, Azizi M, Kirtane AJ, B\u00f6hm M, Mahfoud F (2020) Device-based therapies for arterial hypertension. Nat Rev Cardiol 17:614\u2013628. https:\/\/doi.org\/10.1038\/s41569-020-0364-1","journal-title":"Nat Rev Cardiol"},{"key":"2417_CR6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE et al (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395:1444\u20131451. https:\/\/doi.org\/10.1016\/S0140-6736(20)30554-7","journal-title":"Lancet"},{"key":"2417_CR7","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391:2346\u20132355. https:\/\/doi.org\/10.1016\/S0140-6736(18)30951-6","journal-title":"Lancet"},{"key":"2417_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"6736","author":"M Azizi","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J et al (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 6736:1\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(18)31082-1","journal-title":"Lancet"},{"key":"2417_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.119.040451","volume":"139","author":"M Azizi","year":"2019","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD et al (2019) Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. CIRC J 139:2542\u20132553. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040451","journal-title":"CIRC J"},{"key":"2417_CR10","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 397:2476\u20132486. https:\/\/doi.org\/10.1016\/S0140-6736(21)00788-1","journal-title":"Lancet"},{"key":"2417_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.carrev.2021.01.031","volume":"34","author":"Y Ahmad","year":"2022","unstructured":"Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M et al (2022) Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med 34:112\u2013118. https:\/\/doi.org\/10.1016\/j.carrev.2021.01.031","journal-title":"Cardiovasc Revasc Med"},{"key":"2417_CR12","doi-asserted-by":"publisher","first-page":"E438","DOI":"10.1002\/ccd.29384","volume":"97","author":"M Syed","year":"2021","unstructured":"Syed M, Osman M, Alhamoud H, Saleem M, Munir MB, Kheiri B et al (2021) The state of renal sympathetic denervation for the management of patients with hypertension: a systematic review and meta-analysis. Catheter Cardiovasc Interv 97:E438\u2013E445. https:\/\/doi.org\/10.1002\/ccd.29384","journal-title":"Catheter Cardiovasc Interv"},{"key":"2417_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.numecd.2021.09.007","volume":"32","author":"H Al Ghorani","year":"2022","unstructured":"Al GH, G\u00f6tzinger F, B\u00f6hm M, Mahfoud F (2022) Arterial hypertension- Clinical trials update 2021. Nutr Metab Cardiovasc Dis 32:21\u201331. https:\/\/doi.org\/10.1016\/j.numecd.2021.09.007","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"20","key":"2417_CR14","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.jacc.2022.08.802","volume":"80","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M et al (2022) Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol 80(20):1871\u20131880. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.802","journal-title":"J Am Coll Cardiol"},{"key":"2417_CR15","doi-asserted-by":"publisher","unstructured":"Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res 280\u20138. https:\/\/doi.org\/10.1038\/s41440-022-01042-8","DOI":"10.1038\/s41440-022-01042-8"},{"issue":"10333","key":"2417_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","volume":"399","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE et al (2022) Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 399(10333):1401\u20131410. https:\/\/doi.org\/10.1016\/S0140-6736(22)00455-X","journal-title":"Lancet"},{"issue":"8","key":"2417_CR17","doi-asserted-by":"publisher","first-page":"E677","DOI":"10.4244\/EIJ-D-22-00305","volume":"18","author":"F Rader","year":"2022","unstructured":"Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J et al (2022) Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention 18(8):E677\u2013E685. https:\/\/doi.org\/10.4244\/EIJ-D-22-00305","journal-title":"EuroIntervention"},{"key":"2417_CR18","doi-asserted-by":"publisher","unstructured":"Al Ghorani H., Kulenthiran S., Recktenwald MJM., Lauder L, Kunz M, G\u00f6tzinger F et al (2023) 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension. J Am Coll Cardiol 81(5):517\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.038","DOI":"10.1016\/j.jacc.2022.11.038"},{"key":"2417_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"4","key":"2417_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","volume":"80","author":"G Sesa-Ashton","year":"2023","unstructured":"Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG et al (2023) Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 80(4):811\u2013819. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.20853","journal-title":"Hypertension"},{"key":"2417_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/VHRM.S135253","volume":"13","author":"J Polonia","year":"2017","unstructured":"Polonia J, Azevedo A, Monte M, Silva JA, Bertoquini S (2017) Annual deterioration of renal function in hypertensive patients with and without diabetes. Vasc Health Risk Manag 13:231\u2013237. https:\/\/doi.org\/10.2147\/VHRM.S135253","journal-title":"Vasc Health Risk Manag"},{"key":"2417_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2019.9811","volume":"322","author":"WY Yang","year":"2019","unstructured":"Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF et al (2019) Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA 322:409\u2013420. https:\/\/doi.org\/10.1001\/jama.2019.9811","journal-title":"JAMA"},{"key":"2417_CR23","doi-asserted-by":"publisher","unstructured":"Staplin N, Sierra A De, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M et al (2023) Relationship between clinic and ambulatory blood pressure and mortality\u202f: an observational cohort study in 59 124 patients. 6736(23):1\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(23)00733-X","DOI":"10.1016\/S0140-6736(23)00733-X"},{"issue":"11","key":"2417_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00392-022-02064-5","volume":"111","author":"MA Weber","year":"2022","unstructured":"Weber MA, Schmieder RE, Kandzari DE, Townsend RR, Mahfoud F, Tsioufis K et al (2022) Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clin Res Cardiol 111(11):1269\u20131275. https:\/\/doi.org\/10.1007\/s00392-022-02064-5","journal-title":"Clin Res Cardiol"},{"key":"2417_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1113\/expphysiol.2014.079871","volume":"100","author":"LC Booth","year":"2015","unstructured":"Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP et al (2015) Reinnervation following catheter-based radio-frequency renal denervation. Exp Physiol 100:485\u2013490. https:\/\/doi.org\/10.1113\/expphysiol.2014.079871","journal-title":"Exp Physiol"},{"key":"2417_CR26","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/HYPERTENSIONAHA.118.12250","volume":"73","author":"RR Singh","year":"2019","unstructured":"Singh RR, McArdle ZM, Iudica M et al (2019) Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation. Hypertension 73:718\u2013727. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.12250","journal-title":"Hypertension"},{"key":"2417_CR27","doi-asserted-by":"publisher","unstructured":"Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP et al (2015) Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 65:393\u2013400. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04176","DOI":"10.1161\/HYPERTENSIONAHA.114.04176"},{"key":"2417_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-","volume":"383","author":"H Krum","year":"2014","unstructured":"Krum H, Schlaich MP, Sobotka PA, B\u00f6hm M, Mahfoud F, Rocha-Singh K et al (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383:622\u2013629. https:\/\/doi.org\/10.1016\/S0140-6736(13)62192-","journal-title":"Lancet"},{"key":"2417_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2019.10.048","volume":"13","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, B\u00f6hm M et al (2020) Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 13:471\u2013484. https:\/\/doi.org\/10.1016\/j.jcin.2019.10.048","journal-title":"JACC Cardiovasc Interv"},{"key":"2417_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","volume":"16","author":"RR Townsend","year":"2020","unstructured":"Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP et al (2020) Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 16:89\u201396","journal-title":"EuroIntervention"},{"key":"2417_CR31","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","volume":"40","author":"F Mahfoud","year":"2019","unstructured":"Mahfoud F, B\u00f6hm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L et al (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 40:3474\u20133482. https:\/\/doi.org\/10.1093\/eurheartj\/ehz118","journal-title":"Eur Heart J"},{"key":"2417_CR32","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1161\/01.HYP.0000101695.56635.31","volume":"42","author":"S Vupputuri","year":"2003","unstructured":"Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK et al (2003) Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 42:1144\u20131149. https:\/\/doi.org\/10.1161\/01.HYP.0000101695.56635.31","journal-title":"Hypertension"},{"key":"2417_CR33","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.2215\/CJN.07370714","volume":"10","author":"EK Chowdhury","year":"2015","unstructured":"Chowdhury EK, Langham RG, Ademi Z, Owen A, Krum H, Wing LMH et al (2015) Rate of change in renal function and mortality in elderly treated hypertensive patients. Clin J Am Soc Nephrol 10:1154\u20131161. https:\/\/doi.org\/10.2215\/CJN.07370714","journal-title":"Clin J Am Soc Nephrol"},{"key":"2417_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2215\/CJN.07650711","volume":"7","author":"G Zoppini","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V et al (2012) Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 7:401\u2013408. https:\/\/doi.org\/10.2215\/CJN.07650711","journal-title":"Clin J Am Soc Nephrol"},{"key":"2417_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","volume":"36","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646\u2013661. https:\/\/doi.org\/10.1053\/ajkd.2000.16225","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2417_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/ndt\/14.2.360","volume":"14","author":"R Pontremoli","year":"1999","unstructured":"Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V et al (1999) Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 14(2):360\u2013365. https:\/\/doi.org\/10.1093\/ndt\/14.2.360","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2417_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/HYPERTENSIONAHA.112.193870","volume":"60","author":"F Mahfoud","year":"2012","unstructured":"Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C et al (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 60(2):419\u2013424. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.193870","journal-title":"Hypertension"},{"key":"2417_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00392-020-01595-z","volume":"109","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Townsend RR, Kario K, Kandzari D, Mahfoud F, Weber MA et al (2020) Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medicat. Clin Res Cardiol 109:289\u2013302. https:\/\/doi.org\/10.1007\/s00392-020-01595-z","journal-title":"Clin Res Cardiol"},{"key":"2417_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00392-015-0905-5","volume":"104","author":"S Ewen","year":"2015","unstructured":"Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D et al (2015) Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine\/plasma toxicological analysis. Clin Res Cardiol 104:1097\u20131105. https:\/\/doi.org\/10.1007\/s00392-015-0905-5","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02417-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02417-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02417-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:10:12Z","timestamp":1710749412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02417-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":39,"alternative-id":["2417"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02417-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HA, MJMR and MK do not have COI to declare. SK has received speaker honoraria from Medtronic and ReCor. LL has received speaker honoraria from AstraZeneca,\u00a0Medtronic, Pfizer\u00a0and ReCor. FG received speaker honoraria from AstraZeneca and is supported by the German Foundation for Heart Research\/Deutsche Herzstiftung. SE received speaker honoraria and\/or travel support from Akcea Therapeutics, AstraZeneca, Bayer, Berlin Chemie, Bristol-Myers Squibb\u2014Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Kaneka Pharma, Medtronic, Novartis and ReCor. CU received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic, Pfizer and ReCor. MB is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219, Project-ID 322900939) and reports personal fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Servier, Medtronic, Vifor, Novartis and Abbott. FM is supported by Deutsche Gesellschaft f\u00fcr Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung, received scientific support from Ablative Solutions, Medtronic and Recor. He has received speaker honoraria\/consulting fees from\u00a0his institution (Saarland\u00a0University), Ablative Solutions, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, ReCor, Servier, and Terumo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We have previously\u00a0published results of the change in 24-h blood pressure\u00a0(BP) and renal functions over time as well as\u00a0limited\u00a0safety data in a research letter in JACC under the title '10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension' (JACC VOL. 81, NO.5, 2023, ISSN 0735-1097). Herein, we present the full data set including\u00a0different BP measurement methods, BP control rates, utilization of antihypertensive drugs, and changes in renal resistance indices,\u00a0which are important to assess the efficacy and\u00a0safety of renal denervation in the long term. The present manuscript\u00a0therefore\u00a0differs significantly from the\u00a0research letter\u00a0not only\u00a0regarding\u00a0the type but also the content of the manuscript,\u00a0which\u00a0is novel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of dual publication"}}]}}